Author/Authors :
Zarei Mahmudabadi، Ali نويسنده Department of Biochemical, Chemical Injuries Research Center, Baqiyatallah University of Medical Science, Tehran, Iran , , Masoomi Karimi، Masoomeh نويسنده Department of Immunology, Torbateheydariyeh University of Medical Sciences, Torbateheydariyeh, Iran. , , Bahabadi، Majid نويسنده Department of Biochemistry, Qazvin University of Medical Sciences, Qazvin, Iran , , Bagheri Hoseinabadi، Zahra نويسنده Department of Biochemistry, Rafsanjan University of Medical Sciences, Rafsanjan, Iran , , jafarisani، Moslem نويسنده
Department of Biochemistry, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.
, , Ahmadi، Reza نويسنده Biochemistry Center, Shahrekord University of Medical Sciences, Shahrekord, Iran ,
Abstract :
Vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFRs) play
important roles in angiogenesis of different developmental mechanisms such as wound
healing, embryogenesis and diseases, including different types of cancer. VEGFR2 is associated
with cell proliferation, migration, and vascular permeability of endothelial cells.
Blocking VEGF and its receptors is suggested as a therapeutic approach to prevent tumor
growth. In this study, we aim to block VEGF signaling via small interfering RNA (siRNA)
inhibition of VEGFR2.
Materials and Methods: In this experimental study, we used the RNA interference (RNAi)
mechanism to suppress expression of the VEGFR2 gene. We conducted the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay, real-time polymerase
chain reaction (PCR), Western blot, and flow cytometry analyses of VEGFR2 expression.
Results: Real-time PCR and Western blot results showed that VEGFR2 expression
significantly downregulated. This suppression was followed by inhibition of cell proliferation,
reduction of viability, and induction of apoptosis in the cancer cells.
Conclusion: These findings suggest that VEGFR2 has a role in cell proliferation and
tumor growth. Accordingly, it is suggested that VEGFR2 can be a therapeutic target
for controlling tumor growth and proliferation.
